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ABSTRACT
Primary prevention of cardiovascular disease is governed at present by the risk factor model for
cardiovascularevents,amodelwhichiswidelyacceptedbyphysiciansandprofessionalassociations,
but which has important limitations: most critically, that effective treatment to reduce arterial
damage is often delayed until the age at which cardiovascular events become common. This delay
means that many of the early victims of vascular disease will not be identiﬁed in time. This
delay also allows atherosclerosis to develop and progress unchecked within the arterial tree
with the result that the absolute effectiveness of preventive therapy is limited by the time it is
eventually initiated. The causal exposure model of vascular disease is an alternative to the risk
factor model for cardiovascular events. Whereas the risk factor model aims to identify and treat
those at markedly increased risk of vascular events within the next decade, the causal exposure
model of vascular disease aims to prevent events by treating the causes of the disease when they
are identiﬁed. In the risk factor model, age is an independent non-modiﬁable risk factor and the
predictive power of age far outweighs that of the other risk factors. In the causal exposure model,
age is the duration of time the arterial wall is exposed to the causes of atherosclerosis: apoB
(apolipoprotein B) lipoproteins, hypertension, diabetes and smoking. Preventing the development
of advanced atherosclerotic lesions by treating the causes of vascular disease is the simplest, surest
and most effective way to prevent clinical events.
INTRODUCTION
Forty years ago, given the evidence available, it was
appropriate to label LDL (low-density lipoprotein), BP
(blood pressure) and smoking as risk factors rather than
causes of vascular disease. That stance is no longer
reasonable. All the links in the evidentiary chain of caus-
ality – temporality, strength, dose–response, speciﬁcity,
consistency, biological plausibility and experimental
conﬁrmation – are in place. To pretend there is doubt
is to disregard the masses of interlocking biological,
pathophysiological, epidemiological and clinical trial
results. But if LDL, BP and smoking cause vascular
disease, why are they such weak risk factors for the
likelihood of clinical events? Wald and Law, in particular,
have enunciated and emphasized this paradox [1–3] and
it is a fact that, except at the extremes, the level of LDL,
however it is estimated, the level of BP and the extent of
smoking only marginally inﬂuence the estimates of risk
[4,5].Indeed,WaldandLaw[4]arguethat,althoughLDL
and BP cause vascular disease, they are of no practical
value to identify those who would beneﬁt from prevent-
ive therapy. That is the core of their argument that the
polypill should be given to all those over 55 years of age.
In the conventional sense, this is correct: the causes of
vascular disease are weak risk factors for vascular disease.
However, it does not follow that we should not identify
andtreatthecausesofvasculardiseasewithinindividuals.
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On the contrary, we will try to demonstrate that the
reason that the causes of vascular disease are weak risk
factors for clinical events is primarily a function of how
we treat age as a determinant of vascular disease.
AGE THE DOMINANT RISK FACTOR
Age is, by far, the dominant risk factor in any risk
factor model for cardiovascular events. From 25 years
of age, risk doubles every 8 years [5]. Indeed, once
age and gender are taken into account, all of the
accepted modiﬁable risk factors add only marginally to
the predictive power of the risk factor engines such as
Framingham [6,7]. But does that mean that age ‘causes’
vascular disease? Or does it point to the fact that
the ‘causes’ of vascular disease act progressively over
time?
The most important difference between the risk factor
and causal exposure models is how they treat age. In the
risk factor model, age is regarded as the simple, purely
chronological, variable that it is thought to be in every
daylife,avariable,whichis‘known’tobenon-modiﬁable
and which, operationally, is presumed to be independent
of all the other risk factors. However, age is, in reality,
a complex variable, pointing to, on the one hand, all the
non-modiﬁable biological changes that occur within our
arteries over time and, on the other, all the modiﬁable
consequences of the cumulative injuries to our arteries
over time due to LDL, BP, smoking and diabetes. Put
simply, the injuries to arteries owing to age are due to
exposure and to disintegration [8].
In the risk factor model of cardiovascular events:
Risk = f [age × apo (apolipoprotein) B
× smoking×BP × diabetes]
but actually age represents the duration of exposure of
arteries to apoB, smoking and diabetes.
Therefore in the causal exposure model of vascular
disease:
Disease = (level of apoB × duration of time the arterial
wall is exposed to the apoB lipoproteins) + (level of BP
× duration of time the arterial wall is exposed to BP)
+ (intensity of smoking × duration of smoking)
+ duration of diabetes +
non-modiﬁable changes due to disintegration
STRENGTHS AND LIMITATIONS OF THE RISK
FACTOR MODEL FOR CARDIOVASCULAR
EVENTS
The strengths of the risk factor model are that it is well
known,wellacceptedandthatitworks,thatisitidentiﬁes
risk within broad, but reasonable, limits for the next
decade. To be sure, there are, in fact, multiple risk factor
models: Framingham, SCORE, QRisk and Reynolds.
Nevertheless, their predictions are quite similar because
age is the principal determinant of risk in all.
Events early in life are much less common than events
later in life. That simple reality is what makes age such an
overwhelmingly powerful predictor. But the dominance
of age is also the weakness of the risk factor model. Even
numericallyearlyeventsaccountforanimportantportion
of the total toll of disease and early death is particularly
tragic and costly. Thus, in Framingham, one in six events
in men and one in ten in women occur before 55 years of
age [9]. Moreover, the estimation of risk only holds in the
short-term. Indeed, the majority of those at low short-
term risk are at high long-term risk: in the Framingham
Study,thoseinthelowesttertileof10-yearriskat50 years
of age face a lifetime risk of a coronary heart event almost
as high as those in the highest tertile [10].
Most importantly, a low likelihood of a clinical event
in the next decade does not equal a low likelihood that
disease is not developing within our arterial walls during
that decade. On the contrary, if the causes of vascular
disease are present, there is a high likelihood that it is.
The consequence is that prevention is too often delayed
until disease is advanced and the potential for beneﬁt
from therapy correspondingly reduced. Moreover, there
is a numbers mismatch at the core of the risk factor
model which aims to identify the minority who are at
greatest risk within the next decade, whereas the reality
is the majority, two out of three in the case of the U.S.A.,
will suffer a signiﬁcant cardiovascular event during their
lifetimes [11].
STRENGTHS OF THE CAUSAL EXPOSURE
MODEL: EARLY AND LATE PREVENTION
On the basis of ten large cohort studies in Western
populations,WaldandLaw[5]calculatedthatareduction
in LDL-cholesterol of 1.0 mmol/l at 50, 60 and
70 years of age would reduce vascular events by 56, 41
and31%respectively,demonstratingthatthesamedegree
of LDL-lowering will produce much greater beneﬁt
earlier, rather than later, in life. In the BUPA (British
United Provident Association) study, even though the
absolute number of deaths due to ischaemic heart disease
over a 12-year period was four times greater in those 55–
64 years of age at entry compared with those 35–44 years
of age at entry, reducing cholesterol by 0.6 mmol/l will
preventalmostatwoandahalftimesgreaterpercentageof
fataleventsintheyoungergroupcomparedwiththeolder
one [12]. This evidence supports the pathophysiological
argumentthattheabsolutegainfromtreatingtheyounger
rather than older subjects will be greater, arguing for
earlier compared with later strategies of prevention.
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Vascular disease is not inevitable. Lloyd-Jones and his
co-workers [13] have shown a strikingly low lifetime
incidenceofvasculardiseaseinthosewhodonotmanifest
themajorriskfactorsby50 yearsofage.Thattheduration
of the time arteries are exposed to apoB matters is
illustratedbymutationsinPCSK9(proproteinconvertase
subtilisinkexin9).Gain-of-functionmutationsinPCSK9
result in reduced numbers of LDL-receptors and higher
plasma LDL levels, whereas loss-of-function mutations
result in more LDL-receptor numbers and life-long
lower plasma LDL levels. Strikingly, a gain-of-function
mutation in PCSK9 that results in a reduction in LDL-
cholesterol levels by 30% over a lifetime reduces clinical
events by 88%. This decrease in events per mg of LDL-
cholesterol is substantially more pronounced than the
decrease in events per mg with LDL-lowering therapy
[14]. This ﬁnding of augmented beneﬁt from lifelong
lower levels has been conﬁrmed in other studies of
mutations of this gene [15,16]. Finally, on the basis
of the results of the AMORIS (Apolipoprotein-related
MOrtality RISk) study, reducing the apoB/apoA-I ratio
in all of those above the 80th percentile to the level of
those in the 20th percentile would decrease deaths from
acute myocardial infarction by 80% [17].
WHO SHOULD BE TREATED?
That a very high proportion of the population,
approximately 75%, is at a high total lifetime risk of a
signiﬁcant cardiovascular event should not be surprising
[18],sincethispercentagecorrespondsreasonablyclosely
to the known total incidence of cardiovascular events
in the population [13]. Indeed, this is the core of the
polypill argument to treat all over 55 years of age with a
combination of ﬁxed low-dose pharmacological agents.
Butpharmacologicaltherapywillproduceclinicalbeneﬁt
only in those in whom that speciﬁc cause is present.
Moreover, the degree of beneﬁt will relate to the degree
of abnormality, that is the absolute risk and the absolute
beneﬁt from pharmacological therapy depend on the
absolute levels of the cause(s) of vascular disease. Thus
patients with normal LDL levels but high BP do not
require LDL-lowering therapy, whereas those with very
high LDL levels require more intensive therapy than
thosewithonlymoderatelyelevatedLDLlevels.Targeted
therapy would be more cost-effective than population-
basedsingledosetherapypreciselybecauseitislimitedto
those who need it most. The best choice of the biological
marker of LDL will also improve outcome. For example,
if the ATPIII (Adult Treatment Panel III) guidelines
were applied to the U.S.A. population, substituting non-
HDL (high-density lipoprotein)-cholesterol as the target
of therapy for LDL-cholesterol would result in 300000
more events prevented over a 10-year period. However,
if apoB were substituted for LDL-cholesterol, 800000
more events would be prevented over a 10-year period
[19].
BARRIERS TO IMPLEMENTATION OF THE
CAUSAL EXPOSURE MODEL
In the causal exposure model, therapeutic intervention
would be based on detection of the causes of vascular
disease, not the calculation of short-term risk. Age is the
primary driver of decisions in both the risk factor and
thepolypillmodels.Thereforebothdiscouragetreatment
of the causes of vascular disease in younger people.
The causal exposure model would expand the numbers
selected for early medical prevention of cardiovascular
disease beyond the risk factor model and the polypill
model. Treating more people for longer periods of time
would necessarily change the usual estimates of cost and
beneﬁt.
However, the usual estimates are no longer valid
because medication costs are plummeting. The patent
periods of most of the major statins and antihypertensive
agents have expired or are close to expiring. The price
of generics, particularly in markets such as the U.S.A.,
has diminished dramatically with statins now costing less
than$5permonth.Thereforecostisnotthebarriertocare
it once was. Indeed, treatment of patients at intermediate
risk for cardiovascular events has become cost-effective
[20].
Safety must be a foremost concern. In the short- and
medium-term, the safety of statins and antihypertensive
agents has been established. Nevertheless, long-term
safety cannot be taken for granted and, indeed, only
recently has evidence emerged that the incidence of
diabetes may be slightly increased with long-term
ingestion of statins [21,22]. Naturally, this has been
assumed to be a negative effect of statins, although it
seems possible that this might represent a hazard of
survival free of clinical events.
In any event, the balance of risk and beneﬁt still
strongly favour statin therapy, even when the impact of
a potential increase in the risk of diabetes is taken into
account[20].Thatsaid,trueassuranceoflong-termsafety
willonlycomewithlargenumbersundergoinglong-term
therapy. The reality remains that cardiovascular disease
isthemajorcauseofdeathworldwidenotwithstandingall
the diagnostic tests and therapies that exist. Prevention
is, therefore, the best strategy both from an individual
and a societal perspective.
Ideally, the causal exposure model hypothesis should
be put to the test in a randomized clinical trial. But
this will never occur for many reasons, not least the
several decades such a trial would require. However, it
is possible to model the impact of different strategies to
prevent vascular disease [19,20], and this evidence can be
very helpful. Nevertheless, in the absence of unequivocal
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proof, guideline groups may ﬁnd it impossible to
recommendthecausalexposuremodelandthisalonemay
make widespread implementation impossible. Equally
important,manypatientsarereluctanttotakemedication
and would not accept the equation of potential long-
term gain in exchange for early medical therapy. That,
of course, would be their right. Our view is that patients
shouldbeawareoftherisksthattheyfaceandtheoptions
available to avoid them. The choice is for the patient to
make, a choice, which can be reviewed and revised as
knowledge is gained.
Moreover, all the barriers that apply to early
implementation of therapy to lower LDL also apply to
hypertension and, in the case of hypertension, at least
so far as the guideline groups are concerned and much
of medical practice, they have been overcome. That is to
say, virtually anyone with markedly increased BP will
be offered the option of therapy even if their short- and
medium-term risks of cardiovascular events are low. In
this instance, the knowledge of the long-term hazards
has overcome the barriers to therapy. The difference, we
would contend, is that hypertension is recognized as a
disease, whereas LDL, at least at present, is only a risk
factor for disease.
Deﬁnition of when LDL-lowering therapy should be
initiated needs to be deﬁned for LDL. Early treatment
is accepted when LDL levels are extreme, as in familial
hypercholesterolaemia. Early treatment would not be
accepted if only modest deviations from the norm are
present. The challenge is to ﬁnd the appropriate level at
the appropriate age at which pharmacological therapy
should be considered and this is where studies that
systematically model outcome would be most helpful.
WithregardtoLDL,statinswillbemosteffectiveinthose
who are most abnormal. The younger the individual,
the higher the threshold level for intervention that
will be required. For those above 40 years of age, we
suspect that treatment of those above the 70th percentile
should be cost-effective, but this must be conﬁrmed in
quantitative modelling studies. It might also be helpful
to couple the approach we suggest with appropriate
non-invasive tests of vascular function. Identifying early
abnormalitieswouldgreatlystrengthenthecaseforearlier
intervention. The difﬁculty is the lack of standardization
and physiological validation of some of the most popular
of these tests [23].
SUMMARY
Theriskfactormodelforcardiovasculareventsisbroadly
known and broadly accepted by professionals and
governments, and this facilitates the implementation of
public health policy based on this model. The concept
of appropriately weighting and integrating all of
the relevant information is intuitively attractive and
the method appears authoritative and precise. However,
age, which is conventionally viewed as a non-modiﬁable
risk factor, is the principal determinant of whether
prevention will be initiated in the individual patient,
not the modiﬁable causes of the disease process in the
artery.Onceweappreciatethatagedescribesthelengthof
time over which exposure to the causal factors of disease
occurs, age becomes a modiﬁable risk factor for vascular
disease. Once we couple this understanding with the
recognition that the ability of therapy to prevent clinical
events depends on the extent of disease within the arterial
wall at the time therapy is initiated, the advantages of the
causal exposure model for vascular disease over the risk
factor model for cardiovascular events become apparent.
After all, if disease in the wall is prevented, there will be
no events to predict.
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